IFNA1 and acute myeloid leukemia: An ongoing phase I/II trial has demonstrated that pegylated IFN-α, when administered prophylactically after myeloablative conditioning in an AML cohort at high risk for relapse, did not significantly alter toxicity or acute graft versus host disease (GVHD) risk and produced relatively low rates of relapse suggesting a robust graft versus leukaemia (GVL) response (80).